Agenus Inc (AGEN): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of AGEN were reported in the last 12 months. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Agenus
From the latest filingsOverall: more buying than selling. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns AGEN
102 funds and institutions reported AGEN shares worth $43.9M at the end of Q2 2026, about 37% of the company. The largest holder is BlackRock, Inc. with 6.7%.
Funds and institutions (13F) 37%Everyone else 63%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 2.56M | 6.68% | $7.8M | +370% |
| Vanguard Capital Management LLC | 1.68M | 4.37% | $5.1M | +16% |
| Vanguard Portfolio Management LLC | 1.43M | 3.72% | $4.4M | +19% |
| Siren, L.L.C. | 1.06M | 2.77% | $3.3M | No change |
| Geode Capital Management, LLC | 1.04M | 2.70% | $3.2M | +197% |
| Mackenzie Financial Corp | 714,175 | 1.86% | $2.2M | New |
| Goldman Sachs Group Inc | 448,383 | 1.17% | $1.4M | +1326% |
| Marshall Wace, LLP | 439,621 | 1.14% | $1.3M | -36% |
| Raymond James Financial Inc | 430,078 | 1.12% | $1.3M | +80% |
| Globeflex Capital L P | 418,581 | 1.09% | $1.3M | New |
| State Street Corp | 412,383 | 1.07% | $1.3M | +164% |
| Man Group plc | 340,425 | 0.89% | $1M | +22% |
| Northern Trust Corp | 314,052 | 0.82% | $961K | +250% |
| Connor, Clark & Lunn Investment Management Ltd. | 310,035 | 0.81% | $949K | +56% |
| Vanguard Fiduciary Trust Co | 271,614 | 0.71% | $831K | +35% |
| Morgan Stanley | 262,068 | 0.68% | $802K | -11% |
| Renaissance Technologies LLC | 228,346 | 0.59% | $699K | -20% |
| Panagora Asset Management Inc | 179,589 | 0.47% | $550K | +10% |
| Susquehanna Portfolio Strategies, LLC | 158,737 | 0.41% | $486K | New |
| Jump Financial, LLC | 103,981 | 0.27% | $318K | -34% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No AGEN insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AGEN short interest
High short interest. 16.9% of AGEN shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 43%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 7.60M AGEN shares were sold short, 16.9% of the shares outstanding, up 8.5% from the report before. At the average daily volume of 711,092 shares, buying them all back would take about 10.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 7.60M | 16.87% | +8% | 711,092 | 10.7 |
| Oct 15, 2026 | 7.00M | 15.55% | +3% | 1.08M | 6.5 |
| Sep 30, 2026 | 6.82M | 15.15% | +0% | 1.21M | 5.7 |
| Sep 15, 2026 | 6.80M | 15.11% | +2% | 885,709 | 7.7 |
| Aug 31, 2026 | 6.69M | 14.86% | +14% | 1.10M | 6.1 |
| Aug 14, 2026 | 5.86M | 13.02% | -6% | 1.50M | 3.9 |
| Jul 31, 2026 | 6.23M | 16.23% | -12% | 2.05M | 3.0 |
| Jul 15, 2026 | 7.06M | 18.38% | +18% | 18.44M | 1.0 |
| Jun 30, 2026 | 5.99M | 15.61% | +25% | 1.11M | 5.4 |
| Jun 15, 2026 | 4.78M | 12.44% | -13% | 574,784 | 8.3 |
| May 29, 2026 | 5.46M | 14.23% | +3% | 660,410 | 8.3 |
| May 15, 2026 | 5.32M | 13.84% | +21% | 874,678 | 6.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Agenus company events
Agenus filed 15 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 18, 2026AgreementAgenus West, LLC, a subsidiary of Agenus Inc., and the Company, as guarantor, entered into a Second Loan Modification Agreement with Ocean 1181 LLC relating to the promissory note previously entered into with the Lender on November 26, 2024, as previously amended and restated, and previously… Filing
- Aug 13, 2026LeadershipThe Compensation Committee of the Board of Directors of Agenus Inc. approved a special, one-time performance-based stock option award to Garo H. Armen, Ph.D., the Company’s Chairman and Chief Executive Officer, under and subject to the Company’s Amended and Restated 2019 Equity Incentive Plan. Filing
- Aug 11, 2026LeadershipThe board of directors of Agenus Inc., a Delaware corporation, increased the size of the Board from six (6) to seven (7) directors and appointed Marco Tullio Marcucci to fill the resulting vacancy as a Class II director, to serve until the Company’s 2029 annual meeting of stockholders and until his… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 13, 2026AgreementAgenus Inc. entered into a Securities Purchase Agreement for a private placement with certain institutional and other accredited investors (each, a “Purchaser” and collectively, the “Purchasers”). Filing
- Jul 6, 2026AgreementAgenus Inc. entered into an Amendment to Notes, Extension of Warrants and Sale of New Warrants with existing noteholders, pursuant to which the Company: • extended the maturity date of $5.09 million of senior subordinated promissory notes previously issued by the Company to such noteholders in 2015… Filing
- Jun 23, 2026VoteReported shareholder vote results. Filing
- May 15, 2026LeadershipAustin Charette, Senior Director, Financial Reporting and Compliance and Principal Accounting Officer of Agenus Inc., informed the Company he will be resigning effective May 29, 2026. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Mar 26, 2026AnnouncementThe United States District Court for the District of Massachusetts issued a Memorandum and Order in Byron Olsen, Individually and on Behalf of All Others Similarly Situated v. Filing
- Mar 16, 2026ResultsReleased financial results. Filing
- Jan 16, 2026DealAs previously disclosed, on June 3, 2025, Agenus Inc. and its wholly-owned subsidiary Agenus West, LLC entered into an Asset Purchase Agreement with Zydus Pharmaceuticals (USA) Inc. (subsequently assigned to Zydilac Bio, LLC, “Zydus”), a wholly-owned subsidiary of Zydus Lifesciences Limited, for… Filing
- Jan 14, 2026LeadershipAgenus Inc.'s Board of Directors appointed Dr. Garo Armen, the Company's current Chairman and Chief Executive Officer to serve as the Company's interim Chief Financial Officer and Principal Financial Officer. Filing
- Jan 8, 2026AgreementAgenus Inc., Agenus Royalty Fund, LLC and Agenus Holdings 2024, LLC entered into an amendment and release agreement with Ligand Pharmaceuticals Incorporated related to a Purchase and Sale Agreement and related Warrant each previously disclosed in the Company’s Current Report on Form 8-K filed with… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Agenus financials
Famous investors that hold AGEN
4 of the 50 well-known investors we track reported holding AGEN in their latest 13F filing. The largest position is Jim Simons's, worth $2.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 281,326 | $2.8M | 0.0% | +23% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 150,831 | $1.5M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 124,141 | $1.2M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 16,351 | $162K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named AGEN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | TCG Crossover GP III, LLC | 13G | 10.0% |
| Nov 16, 2026 | TCG Crossover GP III, LLC | 13G | 10.0% |
| Nov 13, 2026 | Eventide Asset Management, LLC | 13G | 5.4% |
| Nov 13, 2026 | Eventide Asset Management, LLC | 13G | 5.4% |
Questions about Agenus Inc (AGEN) stock
Who owns the most AGEN stock?
The largest reported owner of Agenus Inc (AGEN) is BlackRock, Inc., with 6.7% of the company. In total, 102 funds and institutions reported holding AGEN at the end of Q2 2026, together about 37% of the shares. See the largest owners.
Are AGEN insiders buying or selling?
No AGEN insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in AGEN?
As of Oct 30, 2026, 7.60M AGEN shares were sold short, 16.9% of the shares outstanding, up 8.5% from the report before. At the average daily volume of 711,092 shares, buying them all back would take about 10.7 trading days (days to cover). See the history.
Which famous investors hold AGEN?
4 of the 50 well-known investors we track reported AGEN in their latest 13F filing, including Jim Simons, Steve Cohen, Ken Griffin. The largest position is worth $2.8M. See all holders.
Executive pay
Agenus's chief executive was paid a total of $1.4M for the year ended Dec 31, 2025, down 67% from $4.1M the year before. In the last 12 months, Agenus's executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.